Case Report

“Noninfective Endocarditis”: A Case Report of Hereditary Coagulation Disorders in a 28-Year-Old Male

Gregory Reid 1, Luca Koechlin 1, Oliver Reuthebuch 1, Florian Rüter 1, Helmut Hopfer 2, Friedrich Eckstein 1 and David Santer 1,*

1 Department of Cardiac Surgery, University Hospital Basel, 4031 Basel, Switzerland; gregory.reid@usb.ch (G.R.); luca.koechlin@usb.ch (L.K.); oliver.reuthebuch@usb.ch (O.R.); florian.rueter@usb.ch (F.R.); friedrich.eckstein@usb.ch (F.E.)
2 Institute of Medical Genetics and Pathology, University Hospital Basel, 4031 Basel, Switzerland; helmut.hopfer@usb.ch
* Correspondence: david.santer@usb.ch; Tel.: +41-(0)-61-265-25-25

Received: 27 May 2020; Accepted: 5 June 2020; Published: 8 June 2020

Abstract: We report a case of a young male who presented with acute limb ischemia after sport. With no prior history of disease, a non-infective endocarditis of the native aortic valve was diagnosed. After surgical valve replacement, the patient suffered from acute myocardial ischemia under phenprocoumon therapy. Anti-coagulant monitoring was subsequently changed to Factor II analysis after a rare Factor VII deficiency and prothrombin mutation (G20210A) was diagnosed.

Keywords: acute coronary syndrome; anticoagulation; genetic disorders; thrombosis; ultrasound; valve replacement

1. Introduction

The foremost working diagnosis, when a patient presents with acute limb ischemia is an embolus of cardiac source. A large study of 822 cases in 2012 found 79.9% to be of cardiac source, the absolute majority comprising of heart valve disease and atrial fibrillation [1]. The symptoms are often clear, and the 5 P’s (pain, pallor, paresthesia, pulselessness, paralysis) are learned early on by medical students. The diagnostic algorithm includes investigating other potential sources such as atherosclerosis, or emboli originating from an aneurysm sack. Differential diagnosis include trauma, thrombosis following intervention, as well as low flow state and a history of peripheral artery disease. Emboli originating from a heart valve are most commonly due to endocarditis, followed by malignancy. A nonbacterial thrombotic endocarditis (NBTE) is a sub form of culture-negative endocarditis, associated with a number of conditions such as advanced malignancy [2], autoimmune diseases, like systemic lupus anticoagulants, and rheumatoid arthritis. Inherited hypercoagulable conditions include Factor V Leiden, prothrombin gene mutation or an imbalance of clotting and anti-clotting factors.

2. Case Presentation

A 28-year-old male experienced fever and increasing unilateral calf pain after a football game and presented himself to the emergency department the following day. The physical examination showed typical signs of a peripheral arterial occlusion, as well as splinter hemorrhages of the fingernails (Figure 1). The rest of the physical examination was inconspicuous and there were no signs of infection in the otherwise normal blood tests. The patient had no relevant personal medical history, nor family medical history. He had no history of drug or alcohol consumption. The patient’s written consent for use of his data and tissue for research purposes and the subsequent publication were obtained.
The patient, a 53-year-old male, presented with splinter hemorrhages discretely visible on the nails of the right hand (circles) as one of the first symptoms. He had no history of drug or alcohol consumption and his written consent for use of his data and tissue for research purposes and the subsequent publication were obtained.

Ultrasound scan diagnosed an acute embolic closure of the left popliteal artery and the patient underwent immediate embolectomy. Histological examination of the embolus showed thrombotic material without any sign of microorganisms. Further diagnostic workup during hospitalization displayed a visible vegetation with a cross diameter of 6 mm on the bicuspid aortic valve in transthoracic echocardiography and was subsequently confirmed in transesophageal echocardiography (TEE) along with a small patent foramen ovale (PFO). A TEE was seen as a supplemental test for evaluation for cardiovascular source of embolus with no identified noncardiac source [3]. Phenprocoumon was started in therapeutic dose. All blood cultures came up negative and the patient had no neurological symptoms. Empiric antibiotic treatment was initiated.

Six weeks later, TEE demonstrated a sudden progressive growth of the vegetation to $12 \times 12 \times 10 \text{ mm}^3$ and new moderate aortic insufficiency (Figure 2; Supplementary Video S1). Due to the lack of regression, a more complex bleeding disorder seemed unlikely.

---

**Figure 1.** Clinical symptoms. Splinter hemorrhages discretely visible on the nails of the right hand (circles) were one of the first symptoms presented by the patient.

**Figure 2.** Ultrasound video (still). Transesophageal echocardiography performed in the long-axis view at midesophageal level. A visible echogenic mass, consistent with a vegetation of $12 \times 12 \times 10 \text{ mm}^3$ adhered to the native aortic valve.
The indication for urgent aortic valve reconstruction was given by the interdisciplinary heart team. Intraoperatively, the valve was tricuspid with a large vegetation fusing and destructing two leaflets, creating a functionally bicuspid valve (Figure 3). Therefore, a mechanical aortic valve (Medtronic Open Pivot™ AP 360®, 28 mm) was implanted. The histopathological analysis of the vegetation, also using PCR analysis, showed no identification of common or rare pathogens, or organisms. Light microscopy revealed a destructive, ulceropolyposis of the native valve combined with a florid inflammation composed predominantly of leucocytes and fibrin and again no signs of bacterial infection (Figure 4). The patient recovered well and was discharged after a short hospitalization under phenprocoumon therapy with target international normalized ratio (INR) values of 2.0–3.0. Subsequent genetic testing as an outpatient revealed a hereditary heterozygous prothrombin-mutation (G20210A-Mutation).

Seven months later, the patient presented himself again to the emergency ward with chest pain after cycling. High-sensitivity Troponin T was increased to a maximum value of 1521 ng/L (0–14 ng/L) and creatine kinase myocardial band (CK-MB) to 76 µg/L (0–5 µg/L). The coronary angiogram showed multiple, distal coronary embolisms with no signs of atherosclerosis (Supplementary Video S2). In echocardiography a well-functioning mechanical valve prosthesis without any signs of adhering material was observed and there was no change in the left ventricular ejection fraction (LVEF) (60%). No intervention was performed, and the patient was monitored in the intensive care unit. Repeat blood tests including a full coagulation factor panel showed a Factor VII deficiency leading to false high INR values. Anticoagulation monitoring was subsequently changed from INR monitoring to Factor II analysis with target values of 20–25%.
1.31 \[8\]. Mutation could be suspected in individuals with a VTE at an early age or unusual site, or a familial thrombophilia. Routine testing is not recommended \[9\]; however, in these patients, an overlap between elevated plasma prothrombin levels, INR as well as activated partial thromboplastin time (aPTT) and the upper range of reference values is commonly observed. Therefore, normal results might cover pathologic values in these patients. In patients presenting at an unusual age, obtaining a full blood sample before commencing anticoagulation should be considered. Data on this subject are scarce, but patients with suspicious clinical findings, relevant family history or lack of etiology of the embolism might benefit from hematological testing. The presence of a G20210A mutation per se is not an indication for anticoagulation after a thromboembolic event, however, it should be taken into consideration in aggravating circumstances, such as pregnancy, surgery or acute medical illness \[10\].

3. Discussion

Prothrombin (Factor II) is a vitamin K-dependent protein synthesized in the liver and in the coagulation cascade; it is cleaved to form the terminal enzyme thrombin (Factor IIa), that in turn proteolytically cleaves fibrinogen to fibrin. A G20210A mutation results from a base substitution in a non-coding region of the prothrombin gene leading to roughly 30% higher plasma prothrombin levels in homozygote carriers \[5\]. The overall prevalence is estimated around 2% in Caucasian populations \[6\] and it is often seen in combination with Factor V Leiden (FVL). Case-control studies have demonstrated that affected individuals have an increased risk of venous thromboembolism (VTE; odds ratio of 3.1) and even further increase if both mutations are present \[7\]. Meta-analyses have demonstrated the minor significance of the mutation as a risk factor for arterial thrombosis, raising the relative risk to 1.31 \[8\]. Mutation could be suspected in individuals with a VTE at an early age or unusual site, or a familial thrombophilia. Routine testing is not recommended \[9\]; however, in these patients, an overlap between elevated plasma prothrombin levels, INR as well as activated partial thromboplastin time (aPTT) and the upper range of reference values is commonly observed. Therefore, normal results might cover pathologic values in these patients. In patients presenting at an unusual age, obtaining a full blood sample before commencing anticoagulation should be considered. Data on this subject are scarce, but patients with suspicious clinical findings, relevant family history or lack of etiology of the embolism might benefit from hematological testing. The presence of a G20210A mutation per se is not an indication for anticoagulation after a thromboembolic event, however, it should be taken into consideration in aggravating circumstances, such as pregnancy, surgery or acute medical illness \[10\].

In cases necessitating permanent oral anticoagulation, such as a mechanical mitral valve replacement, the recommendations do not differ. Blood coagulation monitoring of the outpatient should include Factor II analyses, alongside INR, as this directly represents the plasma levels of prothrombin. A recent case report by Arletti et al. \[11\] proposes treatment with direct oral anticoagulants (DOACs) for patients suffering from atrial fibrillation and moderate Factor VII deficiency. They highlight again the benefit in an outpatient setting, as DOACs have a differing mechanism of action than phenprocoumon, raising the question if this could be a non-conform treatment option \[12\] for the presented patient, despite the implanted mechanical valve. Retrospective analysis of the pre-operative coagulation panel showed

![Image](image_url)
an off-balance in the Factor II (77%) and Factor VII (38%) levels. This discreet sign could have led to further investigation of possible hereditary deficiencies.

4. Conclusions

Thrombotic vegetations can clinically present as endocarditis. Treatment with full-dose IV unfractionated heparin or subcutaneous low-molecular-weight heparin is suggested (evidence class II-C) [13] and early surgery is reasonable in patients with persistent vegetations despite antibiotic therapy (evidence class IIa-B) or who have mobile vegetations greater than 10 mm in length (evidence class IIb-B) [14]. Prothrombin mutation (G20210A) has a relatively high prevalence and is often seen in conjunction with other coagulation disorders such as Factor V Leiden and Factor VII deficiency. Factor II analysis alongside INR and aPTT monitoring for oral anticoagulant therapy monitoring in these patients should be considered and implemented from the beginning.

Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/2075-4418/10/6/384/s1, Video S1: Ultrasound video. Transesophageal echocardiography performed in the long-axis view at midesophageal level. A visible echogenic mass, consistent with a vegetation of 12 \( \times \) 12 \( \times \) 10 mm\(^3\) adheres to the native aortic valve. Video S2: Coronary angiogram of the left coronary artery. A diagnostic coronary angiogram depicts a lesion in the apical section of the left anterior descending artery (LAD) and no visible sclerosis. No stenting was performed.

Author Contributions: Conceptualization, G.R. and D.S.; methodology, D.S.; software, G.R.; validation, O.R., F.E., and D.S.; formal analysis, G.R. and L.K.; investigation, G.R.; resources, G.R. and H.H.; data curation, G.R.; writing—original draft preparation, G.R. and F.R.; writing—review and editing, G.R., L.K., O.R., F.E., and D.S.; visualization, G.R. and H.H.; supervision, D.S.; project administration, G.R. and F.R.; All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Dag, O.; Kaygin, M.A.; Erkut, B. Analysis of risk factors for amputation in 822 cases with acute arterial emboli. Sci. World J. 2012, 2012, 673483. [CrossRef] [PubMed]
2. Mazokopakis, E.; Syros, P.; Starakis, I. Nonbacterial Thrombotic Endocarditis (Marantic Endocarditis) in Cancer Patients. Cardiovasc. Haematol. Disord. Drug Targ. 2010, 10, 84–86. [CrossRef] [PubMed]
3. Saric, M.; Armour, A.C.; Arnaout, M.S.; Chaudhry, F.A.; Grimm, R.A.; Kronzon, I.; Landec, B.F.; Maganti, K.; Michelen, H.I.; Tolstrup, K. Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism. J. Am. Soc. Echocardiogr. 2016, 29, 1–42. [CrossRef] [PubMed]
4. Sevenet, P.O.; Kaczor, D.A.; Depasse, F. Factor VII Deficiency: From Basics to Clinical Laboratory Diagnosis and Patient Management. Clin. Appl. Thromb. Hemost. 2017, 23, 703–710. [CrossRef] [PubMed]
5. Meeks, S.L.; Abshire, T.C. Abnormalities of prothrombin: A review of the pathophysiology, diagnosis, and treatment. Haemophilia 2008, 14, 1159–1163. [CrossRef] [PubMed]
6. Rosendaal, F.R.; Doggen, C.J.; Zivelin, A.; Arruda, V.R.; Aiach, M.; Siscovick, D.S.; Hillarp, A.; Watzke, H.H.; Bernardi, F.; Cummings, A.M.; et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb. Haemost. 1998, 79, 706–708. [PubMed]
7. Leroyer, C.; Mercier, B.; Oger, E.; Chenu, E.; Abgrall, J.F.; Férec, C.; Mottier, D. Prevalence of 20210A allele of the prothrombin gene in venous thromboembolism patients. Thromb. Haemost. 1998, 80, 49–51. [PubMed]
8. Ye, Z.; Liu, E.H.C.; Higgins, J.P.T.; Keavney, B.D.; Lowe, G.D.O.; Collins, R.; Danesh, J. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. The Lancet 2006, 367, 651–658. [CrossRef]
9. Berg, A.O.; Botkin, J.; Calonge, N.; Campos-Ouralt, D.; Haddow, J.E.; Hayes; M.; Kaye; C.; Klein, R.D.; Offit, K.; Pauker, S.G.; et al. Recommendations from the EGAPP Working Group: Routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet. Med. 2011, 13, 67–76. [CrossRef]
10. Varga, E.A.; Kujovicz, J.L. Management of inherited thrombophilia: Guide for genetics professionals. Clin. Genet. 2012, 81, 7–17. [CrossRef] [PubMed]
11. Arletti, L.; Coluccio, V.; Romagnoli, E.; Luppi, M.; Marietta, M. Direct oral anticoagulants for atrial fibrillation in patients with congenital factor VII deficiency. *Eur. J. Haematol.* 2019, 103, 67–69. [CrossRef] [PubMed]

12. Bertoletti, L.; Benhamou, Y.; Bejot, Y.; Marechaux, S.; Cheggour, S.; Aleil, B.; Lellouche, N.; Dillinger, J.G.; Delluc, A. Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. *Blood Rev.* 2018, 32, 272–279. [CrossRef] [PubMed]

13. Whitlock, R.P.; Sun, J.C.; Frenes, S.E.; Rubens, F.D.; Teoh, K.H. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012, 141, e576S–e600S. [CrossRef]

14. Nishimura, R.A.; Otto, C.M.; Bonow, R.O.; Carabello, B.A.; Erwin, J.P., 3rd; Fleisher, L.A.; Jneid, H.; Mack, M.J.; McLeod, C.J.; O’Gara, P.T.; et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2017, 135, e1159–e1195. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).